Venetoclax for Chronic Lymphocytic Leukaemia Progressing after Ibrutinib: a Multicentre, Open-Label Phase 2 Trial

BACKGROUND: Therapy targeting Bruton’s tyrosine kinase (BTK) with ibrutinib has transformed treatment for chronic lymphocytic leukaemia (CLL). Patients who are refractory or relapse after ibrutinib experience poor outcomes. Venetoclax is a selective, orally bioavailable inhibitor of BCL-2 that has a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Oncol
Main Authors: Jones, Jeffrey A., Mato, Anthony R., Wierda, William G., Davids, Matthew S., Choi, Michael, Cheson, Bruce D., Furman, Richard R., Lamanna, Nicole, Barr, Paul M., Zhou, Lang, Chyla, Brenda, Salem, Ahmed Hamed, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Coutre, Steven, Woyach, Jennifer, Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6027999/
https://ncbi.nlm.nih.gov/pubmed/29246803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30909-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados